Associate Director, Analytical Development and Quality Control (Small Molecules)
- Compensation
- Not disclosed
- Location
- Waltham, MA
- Work setup
- Not specified
- Seniority
- Not specified
- Employment
- Not specified
- Experience
- 8+ years
- Category
- Not specified
- Posted
Must have
- Bachelors degree in Chemistry, Biochemistry, Analytical Sciences, or related field required; advanced degree preferred
- 8+ years of relevant experience in analytical development within the biopharmaceutical or biotechnology industry.
- Strong background in solid oral dosage method development.
- Experience in biologics analytical is a plus.
- Proven experience with method development, validation, and regulatory submissions.
- Deep understanding of ICH, FDA, and EMA regulatory requirements.
- Excellent communication, leadership, and organizational skills.
- Ability to manage multiple programs and priorities in a dynamic environment.
Full description
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody.
We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation – TRUE Innovation!
Position Summary:
The Associate Director of Analytical Development and Quality Control will lead the strategy, development, and execution of analytical methodologies to support small molecules product development from early research through commercialization. The ideal candidate will have deep scientific expertise in method development, QC oversight experience, and a proven ability to work cross-functionally in a fast-paced biotech environment.
Key Responsibilities:
- Develop and execute the analytical development strategy to support small molecules product development across all stages (preclinical to commercial).
- Partner with Process Development, Quality, Regulatory, and Manufacturing to ensure analytical readiness and compliance.
- Oversee development, qualification, validation and transfer of analytical methods for characterization, release, and stability testing.